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Biliary epithelial cells preferentially respond to various insults under chronic pathological 
conditions leading to reactively atypical changes, hyperplasia, or the development of biliary 
neoplasms (such as biliary intraepithelial neoplasia, intraductal papillary neoplasm of the bile 
duct, and cholangiocarcinoma). Moreover, benign biliary strictures can be caused by a variety of 
disorders (such as IgG4-related sclerosing cholangitis, eosinophilic cholangitis, and follicular 
cholangitis) and often mimic malignancies, despite their benign nature. In addition, primary 
sclerosing cholangitis is a well-characterized precursor lesion of cholangiocarcinoma and many 
other chronic inflammatory disorders increase the risk of malignancies. Because of these factors 
and the changes in biliary epithelial cells, biliary strictures frequently pose a diagnostic challenge. 
Although the ability to differentiate neoplastic from non-neoplastic biliary strictures has 
markedly progressed with the advance in radiological modalities, brush cytology and bile duct 
biopsy examination remains effective. However, no single modality is adequate to diagnose 
benign biliary strictures because of the low sensitivity. Therefore, understanding the underlying 
causes by compiling the entire clinical, laboratory, and imaging data; considering the under-
recognized causes; and collaborating between experts in various fields including 
cytopathologists with multiple approaches is necessary to achieve an accurate diagnosis. 
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Biliary epithelial cells lining the biliary tree preferably exhibit reactive changes (such as mild 
papillary hyperplasia and nuclear condensation) and occasionally develop biliary neoplasia [such 
as biliary intraepithelial neoplasia (BilIN) and intraductal papillary neoplasms of bile duct 
(IPNB)] under the pathological conditions of chronic inflammatory biliary diseases and 
cholangiocarcinoma. Although the radiological improvements for the differentiation between 
neoplastic and non-neoplastic biliary strictures have markedly progressed using several recent 
modalities, in patients exhibiting biliary strictures, neoplastic lesions are difficult to differentiate 
from non-neoplastic lesions radiologically. Despite the rarity of these clinical cases, pathological 
examination is still required to distinguish these cases and a bile duct biopsy is effective for 
differentiating benign, inflammatory from malignant or neoplastic lesions. The specimens 
obtained by the choledochoscope are typically small fragments that are comparatively crushed, 
and biliary exfoliative cytology reveals various cellular features irrespective of the tumorous or 
non-neoplastic biliary cells. In this paper, the most recent advances in benign biliary strictures 
and the caution required for diagnosing this condition are reviewed. 
 
Etiology and classification of benign biliary strictures  
A variety of causes can lead to biliary strictures, each with different natural histories and 
responses to therapy. Therefore, determining the underlying etiologies is important to provide 
appropriate treatment. The majority of biliary strictures are malignant and mainly a result of 
pancreatic adenocarcinoma and cholangiocarcinoma, with up to 30 % of these strictures found to 
be benign [1]. The causes of benign biliary strictures are listed in Table 1. Although the actual 
incidence remains unknown and varies among hospital populations, iatrogenic and secondary to 
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biliary injury after cholecystectomy or liver transplantation are the most frequent causes [1]. 
Prior hepatobiliary surgery is responsible for 80 %–90 % of benign biliary strictures [2], and 
chronic pancreatitis is reported to account for 8.2 %–13.9 %, typically with late or end-stage 
chronic pancreatitis [1]. Several immune-mediated inflammatory conditions can lead to biliary 
strictures, most notably primary sclerosing cholangitis, as well as an increasingly recognized 
condition, IgG4-related sclerosing cholangitis (IgG4-SC). Recently, sclerosing cholangitis in 
critically ill patients is believed to have a vascular basis and has also been described [3]. Other 
causes, such as eosinophilic cholangitis, follicular cholangitis, although rare, typically mimic 
hilar cholangiocarcinoma and should also be taken into account when evaluating biliary stenoses 
[4, 5].  
 
There are two established classification systems used to evaluate biliary duct strictures: (1) the 
Bismuth classification based on the location of the stricture; and (2) the Strasberg classification 
system that uses stricture location, size, and bile leakage [6]. Recently, Kaffes have proposed a 
novel classification system with the intention to guide both the assessment and endoscopic 
treatment, as well as the site and common etiology of benign strictures as shown in Table 2 [7] 
 
Cytology and intraductal biopsy for the differentiation of benign from malignant biliary 
strictures  
In presurgical evaluations, testing modalities, including circulating markers, imaging tests, and 
endoscopic tests with tissue sampling are of particular importance and are widely used. However, 
brush cytology and intraductal biopsies obtained via endoscopic retrograde 
cholangiopancreatography (ERCP) have a low sensitivity for the diagnosis of 
cholangiocarcinoma, despite a high specificity. In a meta-analysis published in 2015, the pooled 
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sensitivity and specificity of the brushings were 45 % (95 % confidence interval [CI]: 40 %–
50 %) and 99 % (95 % CI: 98 %–100 %), respectively. The values for the intraductal biopsies 
were 48.1 % (95 % CI: 42.8 %–53.4 %) and 99.2 % (95 % CI: 97.6 %–99.8 %), respectively. A 
combination of both modalities only modestly increased the sensitivity (59.4 %; 95 % CI: 
53.7 %–64.8 %) with a specificity of 100 % (95 % CI: 98.8 %–100 %) [8]. Combining positive 
or atypical cytology with fluorescence in situ hybridization (FISH) achieves a higher sensitivity 
of >70 %, but a lower specificity at 89 % [1]. A triple modality approach, consisting of brush 
cytology, intraductal biopsy, and FISH results in an overall sensitivity of 82 %, specificity of 
100 %, positive predictive value of 100 %, and negative predictive value of 87 % [9]. Sampling 
lesions via endoscopic ultrasonography-guided fine needle aspiration has also been reported to 
increase the diagnostic yield with the pooled sensitivity and specificity for the diagnosis of 
malignant biliary strictures of 80 % (95 % CI: 74 %–86 %), and 97 % (95 % CI: 94 %–99 %), 
respectively [10]. In addition, targeted biopsies by cholangioscopy yielded a pooled sensitivity 
and specificity to detect cholangiocarcinoma of 66.2 % (95 % CI: 59.7 %–72.3 %) and 97.0 % 
(95 % CI: 94.0 %–99.0 %), respectively, in a systematic review published in 2015 [11]. Despite 
advanced, numerous testing modalities and extensive evaluations, the underlying etiology of up 
to 20 % of biliary strictures remains unable to be determined [1]. A multimodality approach to 
carefully consider the clinical, laboratory, and imaging data is needed to optimize the diagnosis 
of biliary strictures.  
 
Benign biliary stricture in surgically resected cases  
In routine works of pathological diagnosis and diagnosing suspicious malignancies in bile duct 
biopsies and/or bile cytological specimens, cases without malignant lesions in surgically resected 
biliary specimens are sometimes encountered. According to Fujita et al. [12] in 2010, 2.8 % (5 of 
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176 cases) of surgically resected biliary specimens have been reported as benign sclerosing 
biliary diseases, consisting primarily of cholangitis in their facility in Japan. Moreover, a meta-
analysis using previous reports from the Japanese and English literature also revealed a relatively 
high frequency of 5 % to 24.5 % [12, 13]. In addition, in the panel discussion of the 49th Annual 
Meeting of the Japan Biliary Association hold in 2013, the results of several Japanese facilities 
revealed that approximately 3 % cases are benign biliary strictures differing from preoperative 
diagnosis. 
As the pathological diagnosis occurs from resected specimens following an operation, biliary 
diseases consist of established causes, including primary sclerosing cholangitis (PSC), IgG4-SC, 
and hepatolithiasis. Additionally, there are also unclassified and nonspecific cholangitis, 
including the recently reported follicular cholangitis described in some case reports. In an actual 
clinicopathological diagnosis, since secondary sclerosing cholangitis caused by extrabiliary and 
iatrogenic diseases, as well as the biliary manifestation of systemic diseases should also be 
considered. Additionally, the information regarding the history of biliary operation and infection 
are required for a pathological diagnosis. The histological manifestation consists of biliary 
stenosis or an obstruction accompanied by inflammation and periductal fibrosis. Furthermore, in 
some diseases, progressive and destructive bile duct lesions and biliary cirrhosis are also found. 
In IgG4-SC, the increased level of serum IgG4 is a valuable indicator, but there are no 
established clinical markers that reflect the disease and the pathological condition of other forms 
of sclerosing cholangitis.  
 
Primary sclerosing cholangitis  
The basic pathology of PSC consists of sclerosing cholangitis in the intrahepatic large bile duct, 
hepatic hilus, and extrahepatic bile ducts. However, these biliary lesions are also found in the 
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secondary sclerosing cholangitis caused by a biliary operation or biliary stone formation. The 
diagnosis of PSC is relatively straightforward when inflammatory bowel diseases (IBD), such as 
ulcerative colitis are present, but exclusive diagnoses are also important. According to reports 
from Europe and North America, IBD is complicated in PSC at a rate of 46.5 %–100 % [14-17] 
with ulcerative colitis being the most common type (47 %–97.6 %) in PSC-IBD [14, 18]. Data 
from the International PSC Study group revealed that 65.2 % of patients with PSC are male, the 
mean age at diagnosis is 40.5 years, and IBD is present in 69 % of PSC patients (79.5 % ulcer 
colitis) [19]. In Japan, the IBD complication rate is relatively low at 34 %, based on the national 
survey of PSC in 2012 [20]. However, the figure for young individuals is higher, at 57 % 
(compared to 12 % in the elderly) [21] and similar to that in Europe and the United States. 
Patients with PSC have been distributed into two peak populations in Japan. However, the 
disease manifestation of IgG4-SC has been broadly recognized, and the contamination of IgG4-
SC cases has been speculated for some of the older PSC cases. According to the recent Japanese 
national survey of PSC, the population of PSC without IgG4-SC cases also exhibited the two 
peak distributions for the age ranges of 35– 40 and 65–70 years [20]. These findings suggest that 
there is a difference in pathogenesis of PSC between young and older individuals. The level of 
genetic diversity among races may also affect the prevalence rate, age at risk for development of 
PSC, as well as the difference in the presence of IBD. Moreover, diffident phenotypes of PSC 
may also exist among various populations.  
Several special PSC populations with differences in clinical features have been described [22-27] 
including small duct PSC, PSC with features of autoimmune hepatitis (AIH) or PSC-AIH 
overlap syndrome, and PSC in children. Patients with small duct disease and features of AIH 
have a significantly (p < 0.001) better transplant-free survival rate and a lower rate of 
hepatobiliary malignancy [19].  Recently, Sarkar et al. [28] postulated that although the actual 
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number may be far smaller, there are more than 3,000 potential PSC phenotypes based on the 
age of diagnosis, presence or absence of IBD, small duct involvement, IgG4 levels, dominant 
strictures, and race. For example, classic PSC, non-IBD large duct PSC, and high IgG4 PSC [28]. 
An association between high serum IgG4 levels and specific human leukocyte antigen (HLA) 
haplotypes has also been reported, suggesting a distinct PSC phenotype [29], in which patients 
may benefit from corticosteroid treatment [30]. However, there have been no confirmed and 
validated diagnostic criteria established to classify PSC phenotypes. 
 
Current evidence suggests that PSC is an immune-mediated disease, but the precise 
etiopathogenesis of PSC remains unclear. The etiology of PSC is thought to be multifactorial, 
including both environmental and genetic causes with 16 genetic risk loci identified to date [24, 
31, 32]. An autoimmune cause is strongly supported by several factors: (1) strong genetic links 
with HLA; (2) tissue infiltration with immune cells; (3) the presence of high circulating 
autoantibody titers; and (4) a clearly increased frequency of concomitant autoimmune disease in 
affected individuals, as well as associated family members [33]. Other putative causes for PSC 
have been suggested, such as mutations in the gene encoding the cystic fibrosis transmembrane 
receptor, recurrent bacterial infections, toxic biliary damage, and vascular insults [23, 24].   
 
In the diagnosis of PSC, an exclusive diagnosis remains important and a comprehensive review 
of relevant clinical information, cholangiogram, and histological findings are required. 
Representative features of PSC are shown in Fig. 1. Histologically, characteristic periductal 
fibrosis (known as onion skin-like fibrosis) is noted in the large intrahepatic and extrahepatic bile 
ducts, and the septal and large bile ducts are selectively absent due to the presence of fibrous 
scars. However, similar periductal fibrosis is found in the intrahepatic small bile ducts in PSC, 
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and similar findings for the small bile ducts have also been found in other biliary diseases that 
involve both intrahepatic large and extrahepatic bile ducts, including IgG4-SC and PSC [34] 
Therefore, the presence or absence of periductal fibrosis in the small bile ducts, especially the 
interlobular and septal bile ducts are unable to differentiate PSC from IgG4-SC [35]. In contrast, 
a biliary biopsy is useful to obtain pathological information concerning malignancy and IgG4-
positive cells.  
There is a need to accurately distinguish PSC from cholangiocarcinoma or IgG4-SC. In general, 
PSC is well known as an important precursor lesion of cholangiocarcinoma. In a 2012 Japanese 
nationwide survey, cholangiocarcinoma was found in 14/197 (7.3 %) of PSC cases [20]. The 
frequencies of cholangiocarcinoma in PSC patients have been reported to range between 2.8 %–
19.9 % worldwide; with the reported lifetime risk for cholangiocarcinoma ranging from 8 % to 
36 % and the 10-year cumulative incidence from 11 % to 31 % [36]. Moreover, PSC often 
accompanies dysplastic lesions (e.g., BilIN), and thus, PSC cases can be suspected of 
cholangiocarcinoma or misdiagnosed as malignant by the biopsy and cytology of the bile ducts 
and its contents. It is important to note that the pooled sensitivity and specificity of the bile duct 
brushings for a diagnosis of cholangiocarcinoma in patients with PSC were 43 % and 97 %, 
respectively [37]. This was achieved with the aid of FISH, whereby the pooled sensitivity 
improved (68 %) but with a lower specificity (70 %) [38]. In addition, elevated serum IgG4 
levels have been found in 6 %–22 % PSC patients [20, 30, 39-42] and a high level of IgG4-
positive plasma infiltration in 23 %–47.5 % [>10/high power field (HPF)] or in 5 %–15.6 % 
(>50/HPF) [41, 43, 44]. This may pose difficulty in the differentiation between PSC and IgG4-
SC. However, IgG4-positive plasma cells are not diffusely present in PSC, and besides IgG4-
positive plasma cell infiltration, the other typical features of IgG4-SC are not observed [43, 44]. 
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IgG4-related sclerosing cholangitis 
IgG4-SC is an IgG4-related systemic condition and a manifestation of biliary disease 
characterized by increased levels of serum IgG4 (>135 mg/dL), marked infiltration of IgG4-
positive plasma cells, and good steroid efficiency. It is similar to other organ involving IgG4-
related diseases, and histologically, sclerosing fibrosis is observed as an organ-specific feature 
[45-47]. In general, IgG4-SC is diagnosed in 13 %–19.5 % of patients with IgG4-related 
systemic disease [48, 49]. IgG4-SC cases without the involvement of other organs are rare, and 
most cases (83 %–95.7 %) are accompanied by type 1 autoimmune pancreatitis (AIP); the 
prevalence and incidence of IgG4-SC in Japan are approximately 1.0 and 0.3 per 100,000 
populations, respectively [48, 50-54]. In addition, about 80 % of patients with AIP suffer 
complications with stenosis of the distal common bile duct [55]. Moreover, IgG4-SC is 
preferably found in older males (male:female = 4:1; mean 67 years), characterized by more than 
90% of patients with IgG4-SC aged 50 or older [49]. Although the disease etiology remains 
poorly understood, allergic and autoimmune reactions against extrinsic or auto-antigens in 
genetically susceptible individuals have been suggested. This hypothesis is based on the 
increased number of eosinophils, the presence of autoantibodies, and the effectiveness of 
immunosuppressive treatments, including steroid therapy [50, 56]. 
  
The diagnosis of IgG4-SC is made through a combination of features, such as imaging, serology, 
histology, the involvement of other organs, and responses to steroid therapy [45, 57]. Elevated 
IgG4 concentrations in the serum play a significant role in the diagnosis of IgG4-SC. Serum 
IgG4 levels are elevated (>135 mg/dL) in 80 %–88 % of patients with IgG4-SC, and in 89.5 % 
patients with IgG4-SC without autoimmune pancreatitis (AIP) [20, 49, 50]. However, the range 
varies widely among studies, and the specificity is limited [53, 58-61]. Elevation of serum IgG4 
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levels is important, but is not necessarily specific to IgG4-SC as the levels may be elevated in 
patients with PSC, cholangiocarcinoma (~15 %), atopic dermatitis, pemphigus, asthma, and even 
a non-selected cohort of patients (approximately 7 %) that visited hospitals for various reasons 
[50, 55, 62]. Besides, nearly 50% of patients with active IgG4-related diseases had normal serum 
IgG4 concentrations in a report from 2015 [63]. It is worth noting that some patients with 
markedly elevated serum IgG4 levels can have false negative levels due to the prozone (or hook) 
effect [64]. Markedly increased IgG4 levels greater than 270 or 208 mg/dL [twice the upper limit 
of normal (2 × ULN)] suggestive of IgG4-SC with a specificity and sensitivity of 90 % and 50 %, 
respectively. However, levels greater than 540 or 560 mg/dL (4 × ULN) have been reported to be 
100 % specific for distinguishing IgG4-SC from cholangiocarcinoma [53, 58]. In patients with 
serum IgG4 levels between 1 and 2 x ULN, the ratio of serum IgG4/IgG > 0.10 or IgG4/IgG1 > 
0.24 is useful for discriminating IgG4-SC from other neoplastic and non-neoplastic biliary 
diseases [65]. Blood plasmablasts, particularly IgG4-positive plasmablasts counts decrease 
substantially after rituximab-mediated B-cell depletion therapy and are identified via flow 
cytometry. Moreover, plasmablast counts could be a potentially useful biomarker for diagnosis, 
assessing response to treatment, and determining the appropriate time for retreatment, as a more 
sensitive analysis than IgG4 concentrations [66, 67]. Furthermore, analyzing the IgG4/IgG RNA-
ratio in the blood by qPCR is also potentially helpful [68].  
 
Representative features of IgG4-SC are shown in Fig. 2. Pathological characteristics of IgG4-SC 
primarily consist of obliterative phlebitis and storiform fibrosis, as well as a marked infiltration 
of IgG4-positive plasma cells (mostly plasmablasts) in the affected bile ducts, which are included 
in the diagnostic criteria of IgG4-SC [45]. Inflammation consists of chronic inflammatory cells 
(e.g., plasma cells and lymphocytes), lymph follicles, and occasionally eosinophils. Differing 
Hiep et al. - 12 
- 
 
from PSC, the inflammation is prominently found in the middle layer of the bile duct wall and 
existing peribiliary glands, rather than in the mucosal layer of the bile ducts. Therefore, biliary 
epithelial cells lining the bile ducts are usually well preserved, and the erosive change and 
neutrophil infiltration are rare in the affected bile ducts. These findings are useful in the 
pathological diagnosis and exfoliative cytodiagnosis of the affected bile ducts [69, 70]. 
Immunostaining for IgG4 displays the marked and typically diffuse infiltration of IgG4-positive 
plasma cells. The proposed cut-off values for IgG4 plasma cells for IgG4-SC are >10 cells/HPF 
for biopsy samples and >50 cells/HPF for surgical specimens. The ratio of IgG4-positive to total 
IgG4-positive plasma cells is greater than 40 % [46]. However, the presence of IgG4-positive 
cells is not the histological hallmark of IgG4-related diseases (including IgG4-SC) because the 
marked infiltration of IgG4-positive cells, while sometimes prominent, are also found in cases of 
PSC and cholangiocarcinoma (43 % of cases exhibited >10 IgG4-positive plasma cells/HPF) [41, 
43, 44, 62, 71]. There have also been a few reported cases of IgG4-SC accompanied by 
cholangiocarcinoma or BilIN lesions, although rare [72-75]. Moreover, cases of IgG4-related 
diseases without the increased level of serum IgG4 or IgG4-positive cells in the affected organs 
have also been reported [76]. These atypical or similar diseases of IgG4-related diseases should 
be recognized, and its pathogenesis is needed for clarification in the future.  
  
Important differential diagnoses of IgG4-SC include cholangiocarcinoma, PSC, and pancreatic 
carcinoma. Indeed, many earlier cases of IgG4-SC have undergone surgery for suspected 
malignancies. Differentiating IgG4-SC cases without pancreatic and other organ involvement 
from PSC or cholangiocarcinoma is challenging [77, 78]. Elevated serum IgG4 concentrations 
are not always helpful for achieving a differential diagnosis, as previously mentioned. If imaging 
is not diagnostic, bile duct biopsy and cytological examination are particularly important to 
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exclude malignancies and establish a diagnosis. However, a potential inflammatory reaction with 
a large number of IgG4-positive plasma cells within or around tumors in cholangiocarcinoma or 
BilIN lesions associated with IgG4-SC should be taken into consideration when diagnosing such 
cases [71]. Other histological features of IgG4-SC (e.g., storiform fibrosis and obliterative 
phlebitis), which can be differentiated from cholangiocarcinoma and PSC, are not located on the 
superficial biliary mucosa. Therefore, it is difficult to identify histological findings from small 
biopsies of the superficial bile duct mucosa, and is impossible to completely exclude 
cholangiocarcinoma during the diagnosis of IgG4-SC by biopsy and cytology. Multiple biopsies 
and specimens from the same site may be needed to identify cancerous or atypical cells [79]. 
Moreover, biopsies from the papilla of Vater [80] and liver [81] can be useful for IgG4-SC 
diagnosis. 
 
Secondary sclerosing cholangitis 
Bile duct stones, inflammatory polyp, biliary tumor, pancreatitis, aneurysm, and iatrogenic 
procedures (e.g., biliary operation) could cause persistent biliary obliteration to develop 
secondary sclerosing cholangitis due to cholestasis and cholangitis. Some cases are accompanied 
by recurrent pyogenic (ascending) cholangitis. Histologically, erosive changes with chronic and 
suppurative inflammation are found in the large bile ducts, and the residual biliary epithelium 
exhibits various reactive and neoplastic changes (e.g., hyperplasia and BilIN) to various degrees 
of severity. However, rare conditions (e.g., eosinophilic cholangitis and follicular cholangitis) 
can present a diagnostic dilemma by mimicking cholangiocarcinoma and other benign conditions 
(including IgG4-SC) due to similarities in some clinical, imaging, and histopathological features. 
Despite this issue, they typically attract less notice due to the rarity and under-recognition of 
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these conditions, leading to misdiagnosis in clinical practice. In the following section, we 
selectively pay particular attention to these two diseases.  
 
Eosinophilic cholangitis 
Eosinophilic cholangitis is a rare, benign, inflammatory condition characterized by a dense 
transmural eosinophilic infiltration of the biliary tract that causes fibrosis, stricturing, and 
obstruction. It is often, but not necessarily associated with peripheral eosinophilia, and responds 
well to oral steroid therapy [4, 82, 83]. This disease was first reported by Leegaard in 1980 in 
relation to cholecystitis with obstructive jaundice [84]. In 1985, Butler et al. reported a case of 
eosinophilic cholangitis with gallbladder wall thickening and focal stricture in the left hepatic 
duct accompanied by eosinophilic infiltration of the cystic duct, gallbladder, lymph nodes, and 
bone marrow [85]. To date, only 38 cases have been documented [82-84, 86-89]. Eosinophilic 
cholangitis can affect a particular region or the entire biliary tract; it is described as localized 
when it involves only a specific portion of the extrahepatic biliary tree and diffused when it 
affects the extrahepatic biliary tree including the gallbladder [83]. Approximately 10 % of 
eosinophilic cholangitis cases involve both the bile duct and gallbladder [82].  
  
Similar to IgG4-SC, eosinophilic cholangitis is believed to be part of a larger spectrum of 
disorders characterized by eosinophilic infiltration of tissues and organ systems, with or without 
concomitant peripheral eosinophilia [4]. All patients with this condition have unexplained 
eosinophilic proliferation. Indeed, multi-organ involvement, including the stomach [4, 86], 
ureters [90], kidneys [91], pancreas [92], lymph nodes, and bone marrow [87] has been described 
in the majority of eosinophilic cholangitis patients. However, there is no clear relationship 
between eosinophilic cholangitis and hypereosinophilic syndrome (HES) described in the 
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literature. Most of the reported eosinophilic cholangitis cases do not appear to have met all of the 
criteria for HES [83]  characterized by: (1) persistent eosinophilia (1500 eosinophils/mm3) for at 
least 6 months, or death before 6 months with signs and symptoms of HES disease; (2) exclusion 
of other recognized causes of eosinophilia; and (3) organ system involvement or dysfunction 
attributable to eosinophil infiltration or not otherwise explained [85].  
Although the exact cause of eosinophilic cholangitis remains poorly understood, there have been 
previously reported associations with cholelithiasis [93], parasitic infection [94], Enterobacter 
aerogenes infection [95], or antibiotic treatment [89, 96]. A relationship between Helicobacter 
pylori infection and eosinophilic diseases has also been documented [82]. However, despite 
these reports, the pathogenesis of eosinophilic cholangitis remains unclear. An allergic 
mechanism is thought to play a key role in the development of this condition. Elevated levels of 
serum IgE, interleukin (IL)-5, and eosinophil cationic protein levels have been reported in the 
majority of cases [83], with about 70% of patients with eosinophilic cholangitis exhibiting 
peripheral eosinophilia [82].   
The diagnosis of eosinophilic cholangitis is based primarily on histological findings. Matsumoto 
et al. have proposed the following diagnostic criteria: (1) wall thickening or stenosis of the 
biliary system; (2) histopathological findings of eosinophilic infiltration; and (3) reversibility of 
biliary abnormalities without treatment, or following steroid treatment [96]. Peripheral 
eosinophilia is one component for the diagnosis of eosinophilic cholangitis, but it is neither 
sensitive nor specific to evaluate the dense eosinophilic infiltration of the bile duct [4, 93]. 
Moreover, peripheral eosinophilia has also been observed in primary biliary cirrhosis 
(cholangitis), primary sclerosing cholangitis, eosinophilic esophagitis, eosinophilic 
gastroenteritis, and IgG4-SC. Histopathologically, the thickening of the bile duct wall [93], 
narrow stenosis, and dilation of the bile duct [97], (revealing diffuse or segmental strictures via 
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imaging), have been observed in most cases [82]. Pseudotumors presenting with multilobulated 
masses encasing and obstructing the common hepatic duct accompanied by similar masses in the 
wall of the gallbladder, or a mass (up to 5 cm in diameter) encasing the porta hepatis 
accompanied by a narrowing of the common bile duct has also been noted [98]. The microscopic 
appearances of eosinophilic cholangitis are characterized by periductal, periglandular fibrosis, 
consisting of a pronounced transmural infiltration of inflammatory cells in the affected bile duct 
comprised prominently of eosinophils that distribute diffusely or form clusters and eosinophilic 
abscesses [4]. Other inflammatory cells, including lymphocytes, plasma cells, histiocytes, and 
lymphoid follicles may also be observed [98]. The bile duct epithelium is intact or displays 
variable changes with regards to the level of eosinophil infiltrate, degeneration, ulceration, 
hyperplasia, and inflammatory/regenerative atypia. The eosinophilic infiltration may involve 
other organs apart from the bile duct, such as the liver, gallbladder, stomach, and pancreas. 
 
Differentiating eosinophilic cholangitis from cholangiocarcinoma is challenging because it can 
mimic cholangiocarcinoma both in clinical presentation and in the radiological characteristics 
[93, 99]. Indeed, most cases of eosinophilic cholangitis reported in the literature were diagnosed 
with suspected cancer of the bile tract and received a retrograde diagnosis following surgery. 
From imaging, eosinophilic cholangitis commonly displays a thickening of the bile duct wall 
(with or without biliary dilatation), and an irregular narrowing appearance has also been noted 
[4]. However, these findings are nonspecific and are also seen in malignant diseases [2]. 
Carbohydrate antigen 19-9 has been commonly used as a screening tool for cholangiocarcinoma, 
but its sensitivity is reported to be only 69 % for the diagnosis of all hepatobiliary malignancies 
[100]. Brush cytology and an intraductal biopsy obtained from the bile duct with eosinophilic 
presentation and without malignancy are important to rule out the possibility of 
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cholangiocarcinoma. However, eosinophilic cholangitis can be difficult to differentiate from 
IgG4-SC or PSC. Peripheral eosinophilia has been observed in 27 % of PSC patients in Japan 
[101]. Moreover, mild-to-moderate peripheral eosinophilia is found in 34 % of patients with 
IgG4-related diseases, and an elevation in the serum concentration of IgG4 in eosinophilic 
cholangitis has been reported [102]. The improvement of the disease after steroid treatment has 
also been noted in IgG4-SC. However, based on the distinctive histopathological features of 
IgG4-SC, PSC and combinations of clinical and laboratory information may facilitate the 
differential diagnosis. The majority of the unresected cases of eosinophilic cholangitis have a 
diffuse type of biliary stricture, severe eosinophilia (>1000/μL), and a stable clinical course with 
steroid treatment [82]. Therefore, although rare, eosinophilic cholangitis should be considered in 
the diagnosis of bile duct strictures, particularly, in the setting of peripheral eosinophilia.  
 
Follicular cholangitis 
Another variant of sclerosing cholangitis is follicular cholangitis characterized by a marked 
periductal lymphoplasmacytic infiltrate, and the presence of numerous lymphoid follicles with 
reactive germinal centers (Fig. 3). This extremely rare clinicopathologic entity preferentially 
affects the hilar bile ducts of adults, represents radiological features suggestive of hilar 
cholangiocarcinoma, and may progress to cirrhosis if left untreated [103]. Since the first case 
reported by Aoki et al. [104], there have been only eight documented cases of follicular 
cholangitis [5, 12, 103-105]. It accounted for 1.1 % (two cases) in a report of 176 cases of hilar 
biliary stricture operations [12]. Follicular cholangitis is a disease of middle-aged to elderly 
patients, with a mean age of 57 years (range 42-73 years) from all reported cases, with a female-
male ratio of 1.7:1. Patients usually present with a gradual progression of the disease, 
characterized by an elevation of serum liver enzymes at the supposed time of onset, a normal 
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serum IgG4 concentration, and negative for antinuclear antibodies. The etiology of follicular 
cholangitis remains unknown, although treatment with corticosteroids may improve the disease 
[105]. 
Histopathology remains the hallmark of follicular cholangitis diagnosis. Macroscopically, 
affected bile ducts exhibit marked irregular wall thickening associated with bile duct dilatation. 
The mucosa of the bile ducts in cases of follicular cholangitis may include moderate stenosis by 
granular nodules that have a “cobblestone-like” appearance, appearing as granular filling defects 
on the cholangiogram or show diffuse, smooth narrowing [5]. Microscopically, the mucosal 
epithelia are usually intact, but may demonstrate inflammation or reproduction resulting in a 
cellular atypia appearance via bile duct brush cytology [105]. The affected bile ducts show dense 
periductal fibrosis with marked lymphoplasmacytic infiltration under the epithelium. In addition, 
there are numerous variable-sized lymphoid follicles surrounding the bile ducts, distributing 
focally or diffusely [12]. The collagenous fibrosis differs from the storiform fibrosis typically 
observed in IgG4-related disease. Lymphoid follicles are well circumscribed, surrounded by an 
intact mantle zone, and are usually contained a germinal center without atypical features of 
lymphocytes and plasma cells. These specific findings are primarily localized at the proximal 
extrahepatic bile ducts and hepatic hilum. The intrahepatic bile ducts are somewhat intact, but 
lymphoid aggregates in the small portal tracts have also been noted [103]. No abnormal findings, 
such as onion skin-like lesions in the intrahepatic peripheral bile ducts have been documented. 
Lymphoid follicles have also been observed in the gallbladder mucosa in some patients with 
follicular cholangitis [103]. Immunohistochemically, the infiltrating lymphocytes consist of 
CD3-positive T cells and CD20-positive B cells; CD4, CD8, and CD79a are also expressed. The 
distribution of λ-chain and κ-chain cells supports the polyclonal nature of B cells and plasma 
cells [103]. Bcl-2 is not expressed in the germinal center [103, 105], and IgG4-positive plasma 
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cells are usually absent. Some cases reported by Zen et al. demonstrated focal-aggregations 
occasionally (range 5 to 21 /HPF), representing 2 %–15 % of the cells, far fewer than that 
expected in IgG4-related disease [46, 103]. Similar histologic findings have been observed in the 
pancreas and the gallbladder, which is termed follicular pancreatitis, or follicular cholecystitis, 
respectively [103, 106, 107].  
It is extremely difficult to differentiate follicular cholangitis from hilar cholangiocarcinoma 
when both are based on clinical and imaging features. The majority of the reported cases were 
treated surgically based on a preoperative diagnosis of cholangiocarcinoma. It may be useful to 
perform cholangioscopy and a biopsy of the lymph gland by endoscopic ultrasound with fine-
needle aspiration for the diagnosis of this disease [105]. From a cytological perspective, the 
presence of atypical epithelial cells may raise concerns of a neoplasm, which creates difficulty 
for a diagnosis. However, histologic features are easily appreciated from the core biopsies of the 
bile ducts and may establish a diagnosis. In addition, follicular cholangitis may mimic PSC when 
bile ducts are more diffusely involved. Indeed, one patient was diagnosed preoperatively with 
PSC and was referred to a hospital for a liver transplantation [103]. However, histopathologically, 
follicular cholangitis exhibits prominent lymph follicles with germinal centers, which can also be 
seen in PSC or IgG4-SC, but are less extensive [69].  Furthermore, follicular cholangitis lacks 
the histologic and immunohistochemical features of IgG4-SC and PSC. Another differential 
diagnosis (although extremely rare) [108], also includes low-grade B-cell lymphomas associated 
with prominent germinal center formation (e.g., follicular lymphoma). The germinal centers in 
follicular cholangitis are negative for Bcl-2 [103, 105], which is in contrast to the follicles of 
low-grade follicular lymphoma which are nearly always Bcl-2 positive [107].  Finally, to obtain 
an accurate diagnosis, follicular cholangitis should be taken into account in the differential 
diagnosis of hilar biliary strictures.  




 Conclusion    
 Biopsy and cytology of bile ducts and bile samples, as well as a frozen section diagnosis of the 
marginal bile duct from a malignancy, are the depressed pathological specimens for general 
pathologists. In addition, the pathological diagnosis is also possibly influenced by the 
radiological findings and the clinical diagnosis. The presence of malignant pathological findings 
indicates a definite pathological diagnosis. However, the gray zones caused by dysplastic lesions, 
and the degenerated changes often found in tiny specimens of the biliary tree area, as well as 
borderline lesions are encountered in resected surgical specimens. In contrast, although many 
malignant and dysplastic lesions are not found in biopsy and cytology, definite malignant lesions 
are often found in surgically resected specimens. Therefore, pathologists should routinely 
perform bold diagnoses, and it is important to communicate such findings with clinicians on a 
daily basis.  
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Table 1 Causes of benign biliary strictures  
Iatrogenic bile duct injury 
  Cholecystectomy 
  Hepatic resection  
  Biliary anastomosis/reconstruction  
  Biliary-enteric anastomosis  
  Liver transplantation  
Anastomotic strictures  
Non-anastomotic strictures 
Biliary immune-mediated inflammation  
  Primary sclerosing cholangitis 
  IgG4-related sclerosing cholangitis 
  Sarcoidosis 
  Mast cell cholangitis  
  Eosinophilic cholangitis 
Choledocholithiasis 
Sphincter of Oddi dysfunction 
Pancreatitis (chronic, autoimmune) 
Cholelithiasis (Mirizzi syndrome) 
Vascular 
  Ischemic cholangiopathy (hypotension, hepatic artery thrombosis) 
  Vasculitis (polyarteritis nodosa) 
  Intra-arterial chemotherapy  
  Portal hypertensive biliopathy 
  Sclerosing cholangitis in critically ill patients 




Post-endoscopic biliary sphincterotomy 




Follicular cholangitis  
Xanthogranulomatous cholangitis 
Inflammatory pseudotumor 
Periportal and peripancreatic lymphadenopathy 
Cystic fibrosis  
Histiocytosis X 
Papillary stenosis (type 1 biliary dysfunction) 
 
 
Table 2 Classification for biliary strictures  
 
Type Site Common etiology Endoscopic treatment 
1 Distal CBD Chronic pancreatitis 
Papillary stenosis 
Multiple plastic stents 
Traditional FCSEMS 
2 Mild extrahepatic duct 







3 Hilar and intrahepatic PSC, autoimmune, 
ischemic  
Balloon dilatation, 
plastic stenting (single 
or multiple) 
4 Surgical billio-enteric 
anastomotic 
Postsurgical  Balloon dilatation  
MPS 
CBD common bile duct, CCY cholecystectomy, FCSEMS fully covered metal stents, MPS 












Legends for figures 
 
Fig. 1 Histological features of primary sclerosing cholangitis 
 a An extrahepatic bile duct with primary sclerosing cholangitis demonstrates that the mucosal 
layer is mainly affected (arrow). b The biliary epithelial layer is distorted (arrow) associated 
with periductal edematous and fibrous thickening (asterisks). c Characteristic periductal fibrosis 
(onion skin-like fibrosis). d Bile loss replaced by a fibrous scar (box). e Higher magnification of 
the fibrous scar 
Fig. 2 Pathology of IgG4-related sclerosing cholangitis. a Full thickening of the bile duct. b 
Transmural fibroinflammatory lesion. c High power of panel b shows lymphoplasmacytic 
infiltration with sparse eosinophils; the biliary epithelial layer is preserved. d Storiform fibrosis. 
e Elastic Van Gieson stain reveals obliterative phlebitis (arrows). f IgG4 immunostaining 
demonstrates numerous IgG4-positive plasma cells, distributing diffusely 
Fig. 3 Follicular cholangitis.  a Marked inflammatory infiltration; higher magnification of the 
bile duct (box) is showed in panel b.  b Periductal fibrosis with numerous variable-sized 
lymphoid follicles. c Lymphoplasmacytic infiltration is found under the epithelium; the biliary 
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Fig. 6  
 
 
 
 
